Form 4: Tourmaline Bio CFO Exits Holdings in Novartis Merger

Tourmaline Bio's CFO, Ryan F. Robinson, disposed of all his common stock and employee stock options as part of the company's acquisition by Novartis AG for $48.00 per share.

Summary

• CFO Ryan F. Robinson disposed of all his common stock and employee stock options in Tourmaline Bio, Inc. on October 28, 2025.
• This transaction was a direct result of the Agreement and Plan of Merger, dated September 8, 2025, with Novartis AG.
• Novartis AG, through its indirect wholly owned subsidiary Torino Merger Sub Inc., completed a cash tender offer to acquire all outstanding shares of Tourmaline Bio, Inc.
• Each share of common stock was acquired for $48.00 in cash.
• Robinson disposed of 14,366 shares of common stock.
• He also disposed of employee stock options covering a total of 176,245 underlying shares, with exercise prices ranging from $9.46 to $17.00.
• All outstanding and unexercised stock options were canceled and converted into a cash payment equal to the difference between the $48.00 merger consideration and the option's exercise price, multiplied by the number of shares.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of an acquisition, resulting in a cash payout for shareholders and option holders at a premium, indicating a positive outcome for those holding equity in Tourmaline Bio.

Positives

• CFO Ryan F. Robinson received a significant cash payout for his common stock and in-the-money employee stock options.
• Shareholders of Tourmaline Bio, Inc. received a definitive cash value of $48.00 per share, representing a premium over the option exercise prices, indicating a favorable exit.

Negatives

• Tourmaline Bio, Inc. will cease to exist as an independent publicly traded company following its acquisition by Novartis AG.
• The reporting person, Ryan F. Robinson, no longer holds any equity or derivative securities in Tourmaline Bio, Inc., thereby losing any potential future upside from the company's independent operations.

Risks

• Loss of future equity participation and potential upside for the reporting person in Tourmaline Bio, Inc. due to the acquisition.

Future Outlook

The filing primarily reports a completed transaction and does not contain forward-looking statements or guidance for Tourmaline Bio, Inc. as an independent entity, given its acquisition by Novartis AG.

Industry Context

The acquisition of Tourmaline Bio by Novartis AG reflects a common trend in the biotechnology and pharmaceutical industry where larger established companies acquire smaller firms to expand their drug pipelines, gain access to novel technologies, or eliminate competition. This particular transaction indicates Novartis's strategic interest in Tourmaline Bio's assets.

Comparison to Industry Standards

• The cash tender offer of $48.00 per share represents a definitive valuation for Tourmaline Bio, Inc. in the context of its acquisition.
• The conversion of in-the-money stock options into cash based on the difference between the merger consideration and exercise price is a standard practice in such M&A transactions, ensuring option holders realize value.
• Without specific deal multiples (e.g., revenue, EBITDA) or comparable company valuations from the merger agreement, a detailed assessment against industry benchmarks for M&A transactions is not fully possible from this filing alone. However, the cash consideration for options with exercise prices significantly below the $48.00 merger price indicates a positive outcome for option holders.

Stakeholder Impact

• Shareholders: Received $48.00 cash per share, realizing immediate and certain value for their investment.
• Employees (specifically option holders): Received cash for their in-the-money stock options, providing a financial benefit.
• Company (Tourmaline Bio): Ceases to exist as an independent entity, becoming part of Novartis AG.

Next Steps

• Integration of Tourmaline Bio, Inc. into Novartis AG's operations.
• Cessation of Tourmaline Bio, Inc. as an independent public entity.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, Form 4, Insider Trading, Stock Options, CFO, Ryan F. Robinson